FDA's Makary Resigns With Agency in Turmoil

FDA Commissioner Marty Makary resigns after 13 months amid policy disagreements and management clashes. Kyle Diamantas takes over as acting commissioner, viewed as a steady hand. Biotech shares reacted to the departure, but the reporter notes this reflects dissatisfaction with Makary rather than optimism about future leadership. - FDA Commissioner Marty Makary resigns after 13 months. - Kyle Diamantas named acting commissioner, seen as a steady hand. - Makary's departure stems from policy disputes and management clashes. - Biotech shares saw a bump, attributed to Makary leaving, not future outlook. - Search for a permanent commissioner through Senate confirmation continues.